Oxford BioMedica (GB:OXB) has released an update.
Oxford BioMedica is set to showcase its expertise in cell and gene therapy at the upcoming Jefferies London Healthcare Conference. With over 25 years of experience, the company plays a pivotal role in developing viral vectors essential for innovative therapies. As a leader in the field, OXB collaborates globally, offering advanced technologies and robust manufacturing capabilities.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
